Moreover, carboxypeptidase B2 has been recognized as a central protein in the plasma of breast cancer patients [76], and its suppression by siRNA has been shown to impede the invasion and migration of breast cancer cells, suggesting its potential as a therapeutic target [77]. Here, CPB2 is linked to breast carcinoma.